Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura [1]

QJM: An International Journal of Medicine

Volumn 98, Issue 11, 2005, Pages 839-840

  Perez Calvo J I ^a   Ruiz Ruiz, F ^a   Amores, B ^a   Torralba, M A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB; RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERANCE; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LETTER; LIVER BIOPSY; LIVER INJURY; MALE; PRIORITY JOURNAL; RELAPSE; SEROLOGY; SPLENECTOMY; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 27744441007     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci130     Document Type: Letter

References (2)

1. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78:275-80.
2. Pérez-Calvo J, Murashige N, Fuertes MA, Kikuchi D, Benito R, Kusumi E, et al. The Safety of Rituximab in Hepatitis C Virus (HCV) Positive Patients. J Appl Res 2004; 4:470-5.